SOPHiA GENETICS (NASDAQ:SOPH) Director Kathy Hibbs Sells 6,250 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $8.13, for a total value of $50,812.50. Following the sale, the director directly owned 96,992 shares of the company’s stock, valued at approximately $788,544.96. This represents a 6.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH traded down $0.07 during midday trading on Thursday, reaching $7.61. The stock had a trading volume of 378,522 shares, compared to its average volume of 261,546. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The stock has a market cap of $638.40 million, a P/E ratio of -6.62 and a beta of 0.98. The firm has a fifty day simple moving average of $6.93 and a two-hundred day simple moving average of $5.65. SOPHiA GENETICS SA has a 12-month low of $3.10 and a 12-month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, equities analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of analyst reports. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. HC Wainwright increased their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS during the 1st quarter worth approximately $50,000. Squarepoint Ops LLC acquired a new position in SOPHiA GENETICS during the third quarter worth $49,000. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the fourth quarter worth $49,000. Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS in the fourth quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new position in shares of SOPHiA GENETICS in the fourth quarter valued at $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.